高级检索
当前位置: 首页 > 详情页

Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110 [2]Department of Traditional Chinese Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000 [3]Department of Pathology,The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
出处:
ISSN:

关键词: matrine hepatocellular carcinoma migration invasion epithelial‑to‑mesenchymal transition PTEN AKT

摘要:
Matrine has been reported to be an effective anti‑tumor therapy; however, the anti-metastatic effects of matrine on hepatocellular carcinoma (HCC) and the molecular mechanism(s) involved remain unclear. Therefore, the aims of the present study were to evaluate the effects of matrine on hepatoma and to determine the associated mechanism(s) involved. In the present study, matrine was confirmed to prevent the proliferation of HCC cells and it was observed that matrine also inhibited the migratory, and invasive capabilities of HCC at non‑toxic concentrations. Additionally, matrine increased epithelial‑cadherin expression and decreased the expression levels of vimentin, matrix metalloproteinase (MMP)2, MMP9, zinc finger protein SNAI1 and zinc finger protein SNAI2. These results indicate that the anti‑metastatic effect of matrine may be associated with epithelial‑mesenchymal transition (EMT). Furthermore, matrine can increase phosphatidylinositol 3,4,5‑trisphosphate 3‑phosphatase and dual‑specificity protein phosphatase PTEN (PTEN) expression and reduce phosphorylated‑protein kinase B (Akt) levels. In conclusion, these results suggested that matrine is a potential therapeutic agent that can suppress cancer‑associated invasion and migration via PTEN/Akt‑dependent inhibition of EMT.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110
共同第一作者:
通讯作者:
通讯机构: [2]Department of Traditional Chinese Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000 [*1]Department of Traditional Chinese Medicine, The First Affiliated Hospital of Harbin Medical University, 122 Youzheng Street, Nangang, Harbin, Heilongjiang 150000, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号